Türk Medline
ADR Yönetimi
ADR Yönetimi

PAZOPANIB OR SUNITINIB AS FIRST-LINE TREATMENT IN METASTATIC RENAL CELL CANCERS: A RETROSPECTIVE COMPARATIVE ANALYSIS OF SURVIVAL AND TOXICITY OUTCOMES

YUNUS EMRE ALTİNTAS,, OGUZCAN KİNİKOGLU,, DENİZ ISİK,, UGUR OZKERİM,, SİLA OKSUZ, TUGBA BASOGLU, HEVES SURMELİ, HATİCE ODABAS, NEDİM TURAN

Eurasian Journal of Medical Investigation - 2025;9(2):97-104

Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Türkiye

 

Objectives: To evaluate and compare the real-world efficacy and safety of pazopanib and sunitinib as first-line treatments in patients with metastatic renal cell carcinoma (mRCC). Methods: This retrospective study included 81 patients with histologically confirmed mRCC who received first-line pazopanib (n=32) or sunitinib (n=49) between 2018 and 2023. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Treatment-related adverse events were assessed and graded according to CTCAE v5.0. Results: Median PFS was 10.7 months with pazopanib and 13.6 months with sunitinib (p = 0.88). Median OS was 54.4 months and 63.3 months, respectively (p = 0.41). No statistically significant differences were found between groups. Univariate analysis showed associations between survival outcomes and nephrectomy or IMDC score, but no independent predictors were identified in multivariate models. Hand–foot syndrome was more frequent with sunitinib, whereas elevated liver enzymes were more common with pazopanib. Fatigue was equally reported in both groups. Grade ?3 toxicities occurred in 43.7% of pazopanib patients and 36.7% of sunitinib patients. Conclusion: Pazopanib and sunitinib demonstrated comparable efficacy in a real-world setting. Differences in safety profiles may help guide treatment selection in environments where access to immunotherapy is restricted.